{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:58:21Z","timestamp":1785484701629,"version":"3.56.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.lrr.2025.100554","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T08:12:06Z","timestamp":1764403926000},"page":"100554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of Rituximab Maintenance on outcomes in Follicular Lymphoma: An Indian experience"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8554-5190","authenticated-orcid":false,"given":"Harish","family":"Pant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Gogia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveet","family":"Wig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari Krishna","family":"Raju Sagiraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumyaranjan","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahitagni","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.lrr.2025.100554_bib0001","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","article-title":"Epidemiology of the non-hodgkin\u2019s lymphomas: distributions of the major subtypes differ by geographic locations","volume":"9","author":"Anderson","year":"1998","journal-title":"Ann. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.lrr.2025.100554_bib0002","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000447577","article-title":"Epidemiology of Non-Hodgkin\u2019s lymphoma in India","volume":"91","author":"Nair","year":"2016","journal-title":"Oncology."},{"issue":"7","key":"10.1016\/j.lrr.2025.100554_bib0003","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.lrr.2025.100554_bib0004","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/annonc\/mds429","article-title":"Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices","volume":"24","author":"Nooka","year":"2013","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.lrr.2025.100554_bib0005","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular Lymphoma International Prognostic Index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.lrr.2025.100554_bib0006","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/leu.2014.251","article-title":"Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a swedish Lymphoma Registry Study","volume":"29","author":"Junl\u00e9n","year":"2015","journal-title":"Leukemia"},{"issue":"9759","key":"10.1016\/j.lrr.2025.100554_bib0007","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"The Lancet"},{"issue":"13","key":"10.1016\/j.lrr.2025.100554_bib0008","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.lrr.2025.100554_bib0009","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/cncr.28659","article-title":"The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States","volume":"120","author":"Nastoupil","year":"2014","journal-title":"Cancer"},{"issue":"27","key":"10.1016\/j.lrr.2025.100554_bib0010","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lrr.2025.100554_bib0011","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J. Clin."},{"issue":"Supplement 1","key":"10.1016\/j.lrr.2025.100554_bib0012","doi-asserted-by":"crossref","first-page":"11979","DOI":"10.1182\/blood-2022-162488","article-title":"Clinical characteristics and outcomes of follicular lymphoma patients with extranodal involvement: analysis of a series of 1090 cases in China","volume":"140","author":"Lin","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.lrr.2025.100554_bib0013","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.21.01234","article-title":"Response-adapted postinduction strategy in patients with advanced-stage follicular lymphoma: the FOLL12 study","volume":"40","author":"Luminari","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lrr.2025.100554_bib0014","article-title":"Evaluation of clinical and pathological features of follicular lymphoma - A three year descriptive study in a regional cancer centre in Western India","volume":"3","author":"Rukmini","year":"2020","journal-title":"Int. J. Oncol. Res. [Internet]."},{"issue":"3","key":"10.1016\/j.lrr.2025.100554_bib0015","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann. Oncol."},{"issue":"9873","key":"10.1016\/j.lrr.2025.100554_bib0016","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"The Lancet"},{"issue":"19","key":"10.1016\/j.lrr.2025.100554_bib0017","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.lrr.2025.100554_bib0018","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.lrr.2025.100554_bib0019","article-title":"Follicular lymphoma: an Institutional analysis","volume":"18","author":"Gogia","year":"2023","journal-title":"Asian Pac. J. Cancer Prev. [Internet]. 2017 Mar [cited"}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:11:25Z","timestamp":1785481885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048925000561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":19,"alternative-id":["S2213048925000561"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100554","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Rituximab Maintenance on outcomes in Follicular Lymphoma: An Indian experience","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100554","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100554"}}